Proteomics rises on US agreement

Shares in Proteomics International Laboratories have jumped more than 8 per cent in early trading, after the Nedlands-based firm announced a collaboration agreement with a US pharmaceutical company.

Under the agreement, Proteomics will partner with Janssen Research & Development to research diabetic kidney disease treatment.

Proteomics launched PromarkerD, a predictive test for early detection of diabetic kidney disease, this year.

Under the collaboration agreement, Janssen will provide samples from its completed clinical trials and Proteomics will perform the sample testing, with joint analysis of the study results.

The analysis is expected to take six to 12 months, with the results to be published following completion.

The study will use PromarkerD as an early predictor of kidney function in patients who took part in Janssen's clinical trials, and assess how the PromarkerD score correlates with drug response in patients with diabetic kidney disease.

The collaboration will also evaluate how PromarkerD performs in predicting heart disease, another major complication arising from diabetes.

Proteomics managing director Richard Lipscombe said the study was an exciting development.

“We are pleased to be working with one of the largest pharma companies to support rapid treatment development for diabetic kidney disease,” he said.

Shares in Proteomics were 8.5 per cent higher at 44 cents each at 12.45pm AEDT.